Emergent Biosolutions (NYSE:EBS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Emergent Biosolutions Inc. (NYSE:EBS)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.81 and traded as high as $12.78. Emergent Biosolutions shares last traded at $12.5250, with a volume of 626,671 shares traded.

Analysts Set New Price Targets

EBS has been the subject of a number of recent analyst reports. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Price Performance

The firm has a market capitalization of $657.81 million, a price-to-earnings ratio of 9.63 and a beta of 2.32. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The business has a 50-day moving average price of $10.82 and a two-hundred day moving average price of $8.81.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The company had revenue of $222.50 million for the quarter. As a group, research analysts forecast that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, Director Ronald Richard sold 21,984 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the sale, the director owned 98,417 shares in the company, valued at approximately $1,178,051.49. This trade represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Coleen Glessner sold 30,608 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares of the company’s stock, valued at approximately $1,443,190. This represents a 17.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.20% of the stock is owned by company insiders.

Institutional Trading of Emergent Biosolutions

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its holdings in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after purchasing an additional 1,020,582 shares during the period. Geode Capital Management LLC raised its position in shares of Emergent Biosolutions by 108.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock worth $8,162,000 after buying an additional 666,708 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Emergent Biosolutions by 313.5% in the 1st quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock worth $4,048,000 after acquiring an additional 631,794 shares during the period. Jain Global LLC bought a new position in shares of Emergent Biosolutions in the third quarter valued at approximately $4,487,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Emergent Biosolutions by 15.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,140,340 shares of the biopharmaceutical company’s stock valued at $18,878,000 after acquiring an additional 291,308 shares during the period. Institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.